ISRCTN87639321 https://doi.org/10.1186/ISRCTN87639321

# The effects of bisphosphonates on disease activity and bone status in ankylosing spondylitis (BIAS)

| Submission date | Recruitment status | [ ] Prospectively registered |
|---|---|---|
| 04/05/2005 | No longer recruiting | [ ] Protocol |
| **Registration date** | **Overall study status** | [ ] Statistical analysis plan |
| 23/05/2005 | Completed | [ ] Results |
| **Last Edited** | **Condition category** | [ ] Individual participant data |
| 03/02/2014 | Musculoskeletal Diseases | [ ] Record updated in last year |

**Plain English summary of protocol**
Not provided at time of registration

## Contact information

**Type(s)**
Scientific

**Contact name**
Dr Ashok Bhalla

**Contact details**
Dept of Rheumatology
Royal National Hospital for Rheumatic Diseases
Upper Borough Walls
Bath
United Kingdom
BA1 1RL
+44 (0)1225 473443

## Additional identifiers

**Protocol serial number**
14585

## Study information

**Scientific Title**

### Acronym
BIAS

### Study objectives
The bisphosphonates will not alter clinical outcome in ankylosing spondylitis

### Ethics approval required
Old ethics approval format

### Ethics approval(s)
Not provided at time of registration

### Study design
Randomised controlled trial

### Primary study design
Interventional

### Study type(s)
Not Specified

### Health condition(s) or problem(s) studied
Ankylosing Spondylitis (AS)

### Interventions
Placebo or Alendronate 70 mg weekly

### Intervention Type
Drug

### Phase
Not Specified

### Drug/device/biological/vaccine name(s)
alendronate

### Primary outcome(s)
BAS-G

### Key secondary outcome(s))
BASDAI, BASFI and BASRI, ESR, CRP, use of NSAIDs, bone density and vertebral deformity.

### Completion date
31/08/2006

## Eligibility

### Key inclusion criteria
Age > 21, stable dose of non-steroidal anti-inflammatory drug (NSAID) for last four weeks. Need to fulfil New York Criteria for AS.

**Participant type(s)**
Patient

**Healthy volunteers allowed**
No

**Age group**
Adult

**Sex**
Not Specified

**Key exclusion criteria**
1. Systemic steroids for the last three months
2. Bisphosphonates in the last 12 months
3. Oesophageal disease or active peptic ulcer
4. Unable to give informed consent
5. Known Paget's Disease
6. Renal disease with creatinine >150 mmol/l, hypercalcaemia, osteomalacia, inflammatory bowel disease, known malignancy and reduced life expectancy <2 years

**Date of first enrolment**
01/08/2004

**Date of final enrolment**
31/08/2006

# Locations

**Countries of recruitment**
United Kingdom

England

**Study participating centre**
**Dept of Rheumatology**
Bath
United Kingdom
BA1 1RL

# Sponsor information

**Organisation**
Royal National Hospital for Rheumatic Diseases (UK)

**ROR**
https://ror.org/05va5gy74

# Funder(s)

**Funder type**
Charity

**Funder Name**
Arthritis Research Campaign 14585

# Results and Publications

## Individual participant data (IPD) sharing plan

**IPD sharing plan summary**
Not provided at time of registration

**Study outputs**

| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Study website | Study website | 11/11/2025 | 11/11/2025 | No | Yes |